This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday – CytomX Therapeutics (NASDAQ:CTMX), Life360 (NASDAQ:LIF)

Jul 31, 2025
this-lexeo-therapeutics-analyst-begins-coverage-on-a-bullish-note;-here-are-top-3-initiations-for-thursday-–-cytomx-therapeutics-(nasdaq:ctmx),-life360-(nasdaq:lif)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Oppenheimer analyst Matthew Biegler initiated coverage on CytomX Therapeutics, Inc. CTMX with an Outperform rating and announced a price target of $7. CytomX Therapeutics shares closed at $2.32 on Wednesday. See how other analysts view this stock.
  • Oppenheimer analyst Leland Gershell initiated coverage on Lexeo Therapeutics, Inc. LXEO with an Outperform rating and announced a price target of $20. Lexeo Therapeutics shares closed at $4.65 on Wednesday. See how other analysts view this stock.
  • Citigroup initiated coverage on Life360, Inc. LIF with a Buy rating and announced a price target of $90. Life360 shares closed at $76.40 on Wednesday. See how other analysts view this stock.

Considering buying CTMX stock? Here’s what analysts think:

Trending Investment Opportunities

Read This Next:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Leave a comment